Discounted Cash Flow Rating

Sell

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Vera Therapeutics, Inc. Class A Common Stock (VERA)

Pharmaceutical Preparations

https://www.veratx.com

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

8000 MARINA BOULEVARD, SUITE 120
BRISBANE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/14/2021

Market Cap

2,060,424,966

Shares Outstanding

44,430,000

Weighted SO

44,432,945

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

THRD --.--%

CGEM --.--%

EWTX --.--%

RLYB --.--%

GLUE --.--%

TVTX --.--%

DICE --.--%

CYTK --.--%

VTYX --.--%

Beta

0.9940

Last Div

0.0000

Range

9.24-50.78

Chg

0.3400

Avg Vol

638727

Mkt Cap

2060424966

Exch

NASDAQ

Country

US

Phone

650 770 0077

DCF Diff

38.3780

DCF

-0.1880

Div Yield

0.0000

P/S

0.0000

EV Multiple

-17.7973

P/FV

6.2729

Div Yield %

0.0000

P/E

-19.0700

PEG

-0.5808

Payout

0.0000

Current Ratio

21.1480

Quick Ratio

21.1480

Cash Ratio

1.3620

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

-1072.6906

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0042

ROA

-0.2715

ROE

-0.4757

ROCE

-0.3094

NI/EBT

1.0000

EBT/EBIT

0.9199

EBIT/Rev

0.0000

Debt Ratio

0.1318

D/E

0.1598

LT Debt/Cap

0.1329

Total Debt/Cap

0.1377

Int Coverage

-1095.6916

CF/Debt

-2.0376

Equity Multi

1.2117

Rec Turnover

0.0000

Pay Turnover

-0.3403

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.9502

FCF/Share

-1.9513

Cash/Share

7.0235

OCF/Sales

0.0000

FCF/OCF

1.0006

CF Coverage

-2.0376

ST Coverage

-50.4390

CapEx Coverage

-1694.1111

Div&CapEx Cov

-1694.1111

P/BV

6.2729

P/B

6.2729

P/S

0.0000

P/E

-19.0700

P/FCF

-19.2938

P/OCF

-19.2703

P/CF

-19.2703

PEG

-0.5808

P/S

0.0000

EV Multiple

-17.7973

P/FV

6.2729

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 10, 23:05 Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Dec 09, 23:29 Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Oct 26, 23:30 Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 GlobeNewswire Inc. May 25, 13:40 Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week The Motley Fool Jan 12, 18:44 Why Vera Therapeutics Stock Soared by 22% This Week Benzinga Dec 18, 13:59 Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst The Motley Fool Dec 15, 10:15 This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street GlobeNewswire Inc. Nov 04, 10:00 Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 GlobeNewswire Inc. Nov 04, 10:00 Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 GlobeNewswire Inc. Nov 04, 10:00 Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Revenue Product Segmentation